Publications by authors named "Aurelien de Pommereau"
Article Synopsis
- Heart failure with preserved ejection fraction (HFpEF) is a serious health issue with few effective treatments available, leading to high morbidity and mortality rates.
- In a study on pigs with HFpEF, researchers tested the impact of cardiosphere-derived cells (CDCs), which have properties that reduce fibrosis and inflammation, on heart function and structure.
- The administration of CDCs significantly improved left ventricular diastolic function and reduced interstitial fibrosis, even though it did not affect left ventricular hypertrophy or systolic function.
Venoarterial extracorporeal membrane oxygenation (VA-ECMO) initiation for patients with cardiogenic shock or cardiac arrest is an attractive strategy since it provides a quick restoration of organ perfusion. One major limitation of VA-ECMO is left ventricle (LV) distension which is associated with poor prognosis. To prevent or treat LV distension, LV decompression may be required.
View Article and Find Full Text PDFBackground: The resorbable magnesium scaffold (RMS) has demonstrated a good safety profile to treat de novo lesions. Nevertheless, bifurcation lesions involving a side branch (SB) >2.0 mm in diameter were excluded from these studies, and such lesions remain technically challenging due to concerns of scaffold deformation or fracture.
View Article and Find Full Text PDFAims: Despite similar efficacy and safety profile in pilot studies, bioresorbable polymer drug-eluting stents (BP-DES) could have potential benefit over latest generation durable polymer (DP)-DES by facilitating vessel healing, therefore reducing inflammation and neoatherosclerosis leading to enhanced clinical safety. Therefore, we sought to perform a meta-analysis of randomized clinical trials (RCTs) comparing the safety and efficacy of everolimus-eluting BP-DES (BP-EES) to second-generation DP-DES.
Methods And Results: We conducted a systematic review and meta-analysis to examine the safety and efficacy of BP-EES in patients treated for coronary artery disease.